Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Envista Holdings's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Envista Holdings's 5-Year Yield-on-Cost % or its related term are showing as below:
MEX:NVST's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.48 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Envista Holdings 5-Year Yield-on-Cost % Related Terms
MEX:NVST vs MMSI, MMED, STVN: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, Envista Holdings's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Envista Holdings 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Envista Holdings's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Envista Holdings's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Envista Holdings (MEX:NVST) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 26, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Envista Holdings and its competitors. According to the industry distribution chart, Envista Holdings ranks #999999 out of 324 companies in the Medical Devices & Instruments industry.
Is Envista Holdings' 5-Year Yield-on-Cost % too high?
Envista Holdings' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Envista Holdings ranks #999999 out of 324 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Envista Holdings has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Envista Holdings' 5-Year Yield-on-Cost % compare to MMSI and MMED?
According to the Medical Devices & Instruments industry distribution chart, Envista Holdings ranks #999999 out of 324 companies for 5-Year Yield-on-Cost %. This places Envista Holdings in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.48, based on 324 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Envista Holdings and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Envista Holdings's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Envista Holdings stock overvalued right now?
Envista Holdings (MEX:NVST) has a current 5-Year Yield-on-Cost % of 0.00. The stock's GF Value™ is MXN336.13, compared to a current price of MXN370.00 — trading 10.1% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Envista Holdings' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Envista Holdings (MEX:NVST), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Envista Holdings (MEX:NVST) Overvalued in 2026?
Based on GuruFocus' analysis, Envista Holdings stock appears to be overvalued.
The current stock price of MXN370.00 is trading 10.1% above its estimated GF Value™ of MXN336.13.
Key valuation signals for MEX:NVST:
5-Year Yield-on-Cost %: 0.00
GF Value™: MXN336.13 vs. price of MXN370.00 (10.1% above fair value)
No single metric tells the full story. See the MEX:NVST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
80GF Score
Get the complete analysis for MEX:NVST
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NVST has been successfully added to your 
